ReproCELL Incorporated
Stock Price Chart
2026/10/02 18:47 UpdatedPrice Trend
2026/10/02 18:47 UpdatedPrice & Trading Details
2026/10/02 18:47 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2025/02/12 | ¥-0.34 | ¥0.80 | +335.3% |
| 2024/08/12 | ¥1.57 | ¥-0.84 | -153.5% |
| 2024/05/12 | ¥-3.62 | ¥-0.94 | +74.0% |
| 2024/02/08 | ¥-0.94 | ¥-0.14 | +85.1% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR INDEX SHARES FUNDS-SPDR Portfolio Developed World ex-US ETF
|
659.6K | -0.27% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
53.0K | 0.00% | |
|
SPDR INDEX SHARES FUNDS-SPDR(R) S&P(R) International Small Cap ETF
|
40.8K | -1.45% | |
|
American Century ETF Trust-Avantis International Small Cap Equity ETF
|
7.8K | 0.00% |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,953M | ¥2,427M | ¥2,979M | ¥2,234M |
| Gross Profit | ¥1,141M | ¥1,121M | ¥1,649M | ¥1,015M |
| Operating Income | -¥356M | -¥409M | -¥130M | -¥860M |
| Pretax Income | -¥304M | -¥409M | -¥130M | -¥860M |
| Net Income | -¥305M | -¥31M | ¥103M | -¥592M |
| EPS | -¥3.62 | -¥0.37 | ¥1.11 | -¥6.25 |
| Operating Margin | -12.06% | -16.87% | -4.38% | -38.51% |
| Balance Sheet | ||||
| Total Assets | ¥8,356M | ¥9,053M | ¥9,671M | ¥9,053M |
| Total Equity | ¥7,575M | ¥8,312M | ¥8,985M | ¥8,312M |
| Total Liabilities | ¥781M | ¥741M | ¥686M | ¥741M |
| Cash | ¥1,915M | ¥2,939M | ¥2,823M | ¥2,939M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 90.66% | 91.81% | 92.91% | 91.81% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥141M | -¥11M | ¥6M | -¥384M |
| Investing CF | -¥1,087M | ¥404M | -¥796M | ¥58M |
| Financing CF | ¥483M | ¥544M | ¥680M | - |
| Free CF | -¥302M | -¥204M | -¥90M | -¥482M |
| Efficiency | ||||
| ROE | -4.03% | -0.38% | 1.15% | -7.12% |
| ROA | -3.65% | -0.35% | 1.07% | -6.54% |
Latest IR Information
-
AMED Subsidy Grant Decision Notice for the Public Offering Project: Infrastructure Development for Industrialization of Regenerative Medicine and Gene Therapy (Task: Development of Manufacturing Process for Tumor-Infiltrating Lymphocytes (TIL) Regenerative Medicine Products for Advanced Cervical Cancer)
Received notice of the subsidy grant decision related to the AMED public offering project. Project period: 2026/9/14 to 2027/3/31. Estimated grant amount for fiscal year 2026 is 79,993 thousand yen; final amount will be confirmed by AMED's notification. No impact...
Read more -
Notice of funds payment completion relating to the issuance of new shares under the Third-Party Allotment and the 19th stock acquisition rights under the Stock Issuance Program
Disclosure of payment completion for 2,932,000 new shares issued through a third-party allotment. Also, 29,320 stock acquisition rights allocated on the same date, with capital increase of approximately 410.48 million yen and funds raised of approximately 549.46 million yen. Allottee:...
Read more -
Notice regarding the issuance of new shares and stock acquisition rights in connection with the 3rd allocation to third parties under the stock and stock acquisition rights issuance program
Through the 3rd allocation to third parties, 2,932,000 ordinary shares are allocated at 140 yen per share to raise approximately 410.48 million yen. The total number of stock acquisition rights is 29,320 rights with an exercise period from 2026/9/4 to...
Read more -
Unknown
Our company has been selected for AMED's publicly funded project, advancing the development of manufacturing processes for tumor-infiltrating lymphocyte (TIL) regenerative medical products for cervical cancer. The research period is up to 3 years, with a subsidy of 92,300 thousand...
Read more -
【ReproCell】Completion of Allotment for New Shares and Stock Acquisition Rights in Third-Party Allotment ｜ July 2026
ReproCell completed the payment for 2,932,000 new shares and 29,320 stock acquisition rights through third-party allotment on July 16, 2026. The total funds raised exceeded 745.21 million yen, which will be allocated to capital stock and capital reserves.
Read more
Latest News (5 items)
Company Information
About
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes. The company also provides Alvetex 3D, a cell culture system; Alvetex, an advanced tissue bioengineering system; EZSPHERE Multiwell Dishes and Plates; KOKEN atelocollagen; ABLE Biott bioreactor systems; and 2mag stirrer systems. In addition, It offers research stem cell, genomics, clinical stem cell research, preclinical and drug discovery, precision medicine, human tissue samples, clinical laboratory, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
